Iintg-HPV method for direct determination of the physical patterns of the HPV genome in relation to the genome of infected cells
The IntG-HPV method uses PCR-Multiplex amplification to directly analyze HPV genome patterns in infected cells, overcoming the limitations of existing indirect methods by providing accurate and cost-effective detection of HPV genome status, enhancing cervical cancer diagnosis and prevention.
Patent Information
- Application Number
- PCT/BR2024/050210
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-23
- Filing Date
- 2024-05-23
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for determining the physical status of the HPV genome in infected cells are indirect, expensive, and provide limited information, only detecting episomal and integrated patterns with poor inference of mixed patterns.
The IntG-HPV method directly determines the episomal, mixed, and integrated physical status of the HPV genome in relation to the genome of infected cells using PCR-Multiplex amplification, analyzing specific amplicons from primer sets of recombinant and non-recombinant regions, allowing for rapid and cost-effective diagnosis and prognosis.
This method provides accurate and direct analysis of HPV genome patterns, enabling effective diagnosis, prognosis, and prevention of cervical cancer and other neoplasms caused by high oncological risk HPV subtypes, with the ability to differentiate between episomal, mixed, and integrated patterns in natural samples.
Smart Images

Figure BR2024050210_28112024_PF_FP_ABST
Abstract
Description
IntG-HPV METHOD FOR DIRECT DETERMINATION OF PATTERNS OF PHYSICAL STATUS OF THE HPV GENOME IN RELATION TO THE GENOME OF INFECTED CELLS
[0001] The present invention relates to the areas of molecular biology and in vitro molecular diagnostics in relation to the direct determination of the patterns of the episomal, mixed and integrated physical status of the genome of the Human Papilloma Virus - HPV and other viruses, which exhibit similar behavior, in relation to the genome of infected cells, applied to the diagnosis and prognosis of cancers, which have as their main cause infection followed by integration of the viral genome into the genome of infected cells, such as Cervical Cancer - CC. In relation to the product of the reagents and kits for the molecular diagnostic test of the patterns of the physical status of the HPV genome in infected cells, such as DNA from CC cell lines and DNA from samples of cervical desquamation cells with low-grade lesions and positive for HPV-16, being determined directly by the IntG-HPV method and preferably amplified by Multiplex PCR.
[0002] The main cause in the etiology of CC is infection by the Human Papilloma Virus – HPV followed by the integration of its genome into the genome of infected cells (Zur Hausen, 2002).
[0003] HPV belonging to the Papillomaviridae family, Papillomavirus genus, are non-enveloped viruses with icosahedral symmetry and a circular, double-stranded DNA genome with approximately 8,000 base pairs (Zheng & Baker, 2006).
[0004] The HPV genome has two main regions: a coding region and a non-coding region. This second region controls transcription and duplication of the viral genome and is called the LCR (long control region). The coding region consists of six genes that are expressed early and two genes that are expressed late, called E (Early) and L (Late), respectively, totaling eight open reading frames (ORFs). The early region, or E, encodes the non-structural proteins: E1, E2, E4, E5, E5, and E7, while the late region, or L, is responsible for the synthesis of the L1 and L2 proteins, which will form the viral capsid (Villa et al. 2002).
[0005] The inactivation of the E2 gene is key in the genesis of CC and other cancers, which are caused by infection with high-risk HPV subtypes followed by the integration of its genome into the genome of the infected cell, since its gene product acts directly in the regulation of the transcriptions of the oncogenic genes E6 and E7, silencing them. When the integration of the viral genome occurs, the E2 gene is inactivated, because the recombination sites between the viral genome and the genome of the infected cell usually occur in the sequence of the E2 gene (Dall et al., 2008).
[0006] The molecular mechanisms related to the malignant phenotype include the role of the E7 protein in inactivating the tumor suppressor protein pRb, and the E6 protein in inactivating the tumor suppressor protein p53, accelerating its proteolytic degradation. The association of viral proteins with tumor suppressor gene products varies according to the oncogenic potential of the HPV subtype (Ghittoni et al., 2010).
[0007] The main high-risk oncological HPV subtypes detected in CC samples are HPV subtypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82, all belonging to the alpha-papillomavirus genus (Castellsagué et al., 2016).
[0008] HPV subtypes 16 and 18 are the most prevalent, representing 70% of cases and having the greatest geographic distribution in the world (de Sanjose et al., 2010).
[0009] The rates of viral integration found in carcinomas resulting from infection by HPV subtypes 16 and 18 using indirect methods are approximately between 80% and 100%, respectively (Pett & Coleman, 2007).
[0010] The evolution of CC, considering the patterns of the physical status of the genome of high-risk HPV subtypes in relation to the genome of infected cells, comprises three stages: the first or initial stage, which is characterized by viral infection with maintenance of the integrity of the viral genome in a circular or episomal pattern. At this stage, there is the possibility of regression of the infection and the lesion; the second or intermediate stage, characterized by the coexistence of the episomal and integrated patterns, called a mixed pattern; and the third or late stage, characterized only by the presence of the integrated pattern. Stages that present the integrated pattern are responsible for the carcinogenic process, with no possibility of regression in 99% of cases (Vinokurova et al., 2008).
[0011] The main PCR-based protocols that suggest the indirect analysis of the physical status of the HPV genome compared to the genome of infected cells are: a) amplification of HPV oncogenic transcripts (Klaes et al., 1999), b) amplification and relative analysis between the E2 and E6 genes (Yoshinouchi et al., 1999), c) amplification of the integrated HPV sequence by franking with cellular sequences (DIPS) (Luft et al., 2001) and d) amplification of the fusion region using specific primers and restriction enzymes (Thorland et al., 2000).
[0012] In patent material dealing with the physical status of the HPV genome, in 2002, inventors Lorincz & Lazar related the relative analysis between the expressions of the E6 and E7 genes, depending on the coefficient obtained, the integrated condition of HPV in infected cells can be inferred (US6355424).
[0013] The IntG-HPV molecular method is characterized as a disruptive innovation in the areas of molecular biology for diagnosis, prognosis, screening and prevention of Cervical Cancer, among other neoplasms, which are caused by high-risk HPV subtypes in natural samples, since it directly determines the patterns of the episomal, mixed and integrated physical status of the viral genome in relation to the genome of infected cells, at low cost, quickly and with national technology.
[0014] The aforementioned methods provide indirect analyses, are expensive, and have limited information. As a result, they suggest only episomal and integrated patterns, with the mixed pattern being achieved through poor inference (Woodman et al., 2007).
[0015] The molecular method IntG-HPV directly determines the patterns of the episomal, mixed and integrated physical status of the viral genome in relation to the genome of infected cells, at low cost, quickly and using in natura samples.
[0016] The molecular method IntG-HPV is characterized as a disruptive innovation in the areas of molecular biology for diagnosis, prognosis, screening and prevention of Cervical Cancer, among other neoplasms, which are caused by high-oncological risk HPV subtypes. Fig. 1
[0017] [Fig. 1] Presents the results of the amplification of the Multiplex PCR reaction of the IntG-HPV method in samples previously genotyped for HPV-16 in cervical desquamation cells with low-grade lesions and in a DNA sample from the CCUSiHa cell line, evidencing the episomal and integrating patterns of HPV-16, respectively. Fig.2
[0018] [Fig. 2] Presents the results of the amplification of the Multiplex PCR reaction of the IntG-HPV method in samples previously genotyped for HPV-16 in cervical desquamation cells with low-grade lesions and in a DNA sample from the CCUCa Ski cell line, evidencing the episomal and mixed patterns of HPV-16, respectively. Fig. 3
[0019] [Fig. 3] Presents the results of the amplification of the Multiplex PCR reaction of the IntG-HPV method in samples previously genotyped for HPV-16 in cervical desquamation cells with low-grade lesions and in a DNA sample from the CCUCa Ski cell line and a DNA sample from the CCUSiHa cell line, evidencing the episomal, mixed and integrated patterns of HPV-16, respectively.
[0020] The IntG-HPV METHOD FOR DIRECT DETERMINATION OF PATTERNS OF THE PHYSICAL STATUS OF THE HPV GENOME IN RELATION TO THE GENOME OF INFECTED CELLS targets HPV regions that directly determine the patterns of the Episomal, Mixed and Integrated physical status of the HPV genome in relation to the genome of the infected cell, but is not limited to the diagnosis and prognosis of HPV infection in the screening and prevention of CC.
[0021] The IntG-HPVi method is innovative in directly determining the integration of the viral genome into the genome of the infected cell and can be applied to other viruses that have a circular DNA genome and exhibit molecular behavior similar to HPV, such as human polyomavirus, which causes Merkel cell skin cancer (Feng et al. 2018).
[0022] The innovation of the IntG-HPV method consists of the direct determination of the patterns of the physical status of Episomal, Mixed and Integrated of the genome of high-risk HPV subtypes in natural samples of desquamated cells and / or biopsies of the genital tract, among others, amplified preferentially by Multiplex PCR in recombinant and non-recombinant regions of the HPV genome in relation to the genome of infected cells.
[0023] The IntG-HPV METHOD FOR DIRECT DETERMINATION OF PATTERNS OF THE PHYSICAL STATUS OF THE HPV GENOME IN RELATION TO THE GENOME OF INFECTED CELLS, comprises two (2) steps, namely:
[0024] From the prior determination of the high-risk HPV subtype, the first step is the application of the IntG-HPV Method, which is characterized by the production of specific amplicons from the primer sets of the recombinant and non-recombinant regions of the HPV genome in relation to the genome of the infected cells, preferably by Multiplex-PCR;
[0025] The second stage is characterized by the amplicon analysis processes, which determine the Episomal, Mixed and Integrated molecular patterns;
[0026] The details of the invention are found in the following paragraphs.
[0027] The IntG-HPV method consists of producing specific amplicons from primer sets of the recombinant and non-recombinant regions of the HPV genome in relation to the genome of infected cells, preferably by Multiplex PCR. The results can be analyzed using either Real Time PCR or polyacrylamide (PAG) or agarose gels. Integration of the HPV genome into the genome of infected cells is a determining factor for the establishment and progression of the neoplastic process in infected tissues, such as cervical cells, which, when infected and subsequently integrated with the HPV genome, develop into CC.
[0028] Therefore, the IntG-HPV method presents an innovative approach for determining the physical status of the HPV genome, especially of high-risk HPV subtypes, such as HPV-16. This method determines the change in the HPV genome from the episomal form to the integrated form directly in infected cells, providing a direct method for determining the integration of the high-risk HPV subtype genome into the genome of infected cells.
[0029] The IntG-HPV method analyzes the regions of the E1, E2, E4, E5, E6, and E7 genes of the HPV subtype of interest. In the episomal pattern, amplicons specific to the HPV subtype of interest are generated. In the integrated pattern, depending on which recombination site participates in the integration mechanism, there will be an absence of specific amplicons.
[0030] The amplification of the IntG-HPV method was preferably performed by Multiplex PCR using DNA samples from the CCUSiHa, Ca Ski cell lines and 35 DNA samples from cervical desquamation cells with low-grade lesions and positive for HPV-16, preferably in a final volume of 50μL, with 4μL of the primer mix at a concentration of 100pMol for each recombination region and 2μL of samples (maximum 50ng of DNA per reaction), 19μL of DNAse and RNAse-free ultrapure water and 25μL of MasterMix2X (with DNA polymerase Hot start).
[0031] The set of primers used in the Multiplex PCR of the IntG-HPV method for HPV-16 preferably correspond to the sequences: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6 and SEQ ID NO: 7.
[0032] The conditions of the Multiplex PCR reaction of the IntG-HPV method were preferably 1 cycle of 95°C for 3 minutes and 40 cycles, being 95°C for 30 seconds, 62°C for 1 minute and 30 seconds and 72°C for 2 minutes, and 1 final extension cycle of 72°C for 5 minutes.
[0033] As an example of the episomal physical status of the HPV-16 genome, when amplified by Multiplex PCR of the IntG-HPV method, the amplicons 88bp, 313bp, 450bp and 657bp are preferentially generated.
[0034] The absence of the 657bp amplicon is associated with the integration site of the HPV-16 genome, involving the regions adjacent to the E7 gene in a clockwise direction.
[0035] The absence of the 313bp amplicon is associated with the integration site of the HPV-16 genome, involving the regions adjacent to the L2 gene in a counterclockwise direction.
[0036] The absence of the 88bp and 657bp amplicons is associated with the integration site of the HPV-16 genome, involving the regions adjacent to the E7 gene in a clockwise direction.
[0037] Once the HPV-16 genome has integrated into the genome of infected cells, the 450-bp amplicon is produced from the non-recombinant regions. Thus, its amplification is constant and serves as a reference for determining the mixed pattern.
[0038] To differentiate the mixed pattern from the episomal pattern, it is necessary to establish the Relative Ratio (RR) between the intensity or amplification of the constant amplicon and the intensity or amplification of the "non-constant" amplicons separately. If the RR is less than or equal to 1 for each amplicon analyzed, the HPV genome is in the episomal or non-integrated pattern. When the RR is greater than 1 for any amplicon analyzed, the HPV genome is in the integrated pattern with the genome of the infected cells.
[0039] The Relative Ratio is calculated by dividing the intensity or amplification value of the amplicon constant (IA) k ) by the intensity or amplification value of the amplicon (IA) n) for each amplicon.
[0040] The percentage of integration of the HPV subtypes of interest is calculated by multiplying the Relative Ratio by 100 and dividing the product by the intensity or amplification value of the amplicon constant (IA). k ).
[0041] Modifications to some details regarding the method's implementation may be introduced. These modifications will not imply a change in the fundamental principles set forth in the claims. The examples described below illustrate, but do not limit, the nature of the invention. Examples
[0042] Example 1: Analysis of the physical status of the HPV-16 genome in a DNA sample from the CCUSiHa cell line using the IntG-HPV method. The IntG-HPV method was validated on a DNA sample extracted from the CCUSiHa cell line, which is a suitable in vitro model for this purpose. This cell line was immortalized by the integration of the HPV-16 genome and established in 1970 from a CC sample from a 55-year-old patient (Friedl F, et al. 1970). The amplifications by multiplex PCR reaction of the IntG-HPV method were performed in duplicate, as well as in samples of cervical desquamation cells (N = 35 samples) with low-grade lesions and positive for HPV-16, being preferably used in the final volume of 50μL, being 4μL of the primer mix at a concentration of 50pMol for each recombination region and 2μL of samples (maximum 50ng of DNA per reaction), 19μL of ultrapure water free of DNAse and RNAse and 25μL of MasterMix2X with DNA polymerase Hot start and 2% DMSO.The set of primers of the IntG-HPV method for HPV-16 preferably correspond to the sequences: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6 and SEQ ID NO: 7. The preferred conditions of the Multiplex PCR reaction of the IntG-HPV method were 1 cycle of 95°C for 3 minutes and 40 cycles, being 95°C for 30 seconds, 62°C for 1 minute and 30 seconds and 72°C for 2 minutes, and 1 final extension cycle of 72°C for 5 minutes. The results of the IntG-HPV method in DNA from the SiHa CC cell line when compared to samples of cervical desquamation cells with low-grade lesions and positive for HPV-16 by Fisher's Exact Test, showed statistically significant differences with a p-value > 0.05.Thus, the results of the IntG-HPV method suggest the association of the Episomal pattern of the HPV-16 genome with the genome of the uterine cervix desquamation cells with low-grade lesions and the association of the Integrated pattern of the HPV-16 genome with the genome of the CCUSiHa cell line through the absence of the 88bp and 657bp amplicons, which are associated with the recombination site of the HPV-16 genome, involving the regions adjacent to the E7 gene in a clockwise direction, as shown in Figure 1.
[0043] Example 2: Analysis of the physical status of the HPV-16 genome in a DNA sample from the CCUCa Ski cell line by the IntG-HPV Method. The IntG-HPV method was validated on a DNA sample extracted from the CCUCa Ski cell line. This cell line can be used in testing and calibration in ISO 17025 accredited laboratories to challenge assay performance, validate or compare test methods, and establish sensitivity, linearity, and specificity during the validation or implementation of in vitro molecular diagnostic assays (ATCC, 2022). The CCUCa Ski cell line was immortalized by the integration of a few copies of the HPV-16 genome and established in 1977 from cervical carcinoma epidermoid cells of a 40-year-old patient (Pattillo et al., 1977).The amplifications of the Multiplex PCR reaction of the IntG-HPV method were performed in duplicate, as well as in samples of cervical desquamation cells (N = 35 samples) with low-grade lesions and positive for HPV-16, being preferably used in the final volume of 50 μL, being 4 µL of the primer mix at a concentration of 50 pMol for each recombination region and 2 µL of samples (maximum 50 ng of DNA per reaction), 19 µL of DNAse and RNAse-free ultrapure water and 25 µL of MasterMix 2X with DNA polymerase Hot start and 2% DMSO. The set of primers of the IntG-HPV method for HPV-16 preferably correspond to the sequences: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6 and SEQ ID NO: 7. The preferred conditions for the Multiplex PCR reaction of the IntG-HPV method were 1 cycle of 95°C for 3 minutes and 40 cycles, being 95°C for 30 seconds, 62°C for 1 minute and 30 seconds and 72°C for 2 minutes, and 1 final extension cycle of 72°C for 5 minutes.The results of the IntG-HPV method in DNA from the CCUCa Ski cell line when compared to samples of cervical desquamation cells with low-grade lesions and positive for HPV-16 by Fisher's exact test showed a statistically significant difference (p-value > 0.05). Thus, the results of the IntG-HPV method suggest the association of the Mixed pattern of the HPV-16 genome with the genome of the CCUCa Ski cell line and the association of the Episomal pattern of the HPV-16 genome with the genome of cervical desquamation cells with low-grade lesions. Therefore, the Ca Ski cell line presents a reduction in the intensity of the 657 bp amplicon, which is associated with the recombination site of the HPV-16 genome, involving the regions adjacent to the E7 gene in a clockwise direction, as shown in Figure 2.
[0044] Example 3: Analysis of the physical status of the HPV-16 genome in DNA from cervical desquamation cells with low-grade lesions and positive for HPV-16 by the IntG-HPV method. The IntG-HPV method was validated in DNA samples from cervical desquamation cells (N = 35 samples) with low-grade lesions and positive for HPV-16. The amplifications of the Multiplex PCR reaction of the IntG-HPV method were performed in duplicate using as positive control for the Integrated and Mixed standards the DNA of the CCUSiHaeCaSki cell lines, respectively, being preferably used in the final volume of 50μL, being 4μL of the primer mix at a concentration of 50pMol for each recombination region and 2μL of samples (maximum 50ng of DNA per reaction), 19μL of ultrapure water free of DNAse and RNAse and 25μL of MasterMix2X with DNA polymeraseHot start and 2% DMSO.The set of primers of the IntG-HPV method for HPV-16 preferably correspond to the sequences: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6 and SEQ ID NO: 7. The preferred conditions of the Multiplex PCR reaction of the IntG-HPV method were 1 cycle of 95°C for 3 minutes and 40 cycles, being 95°C for 30 seconds, 62°C for 1 minute and 30 seconds and 72°C for 2 minutes, and 1 final extension cycle of 72°C for 5 minutes. The results of the IntG-HPV method in DNA from the CCUSiHa and Ca Ski cell lines when compared to samples of uterine cervix desquamation cells with low-grade lesions and positive for HPV-16 by Fisher's Exact Test showed a statistically significant difference (p-value > 0.05).Thus, the results obtained by the IntG-HPV method suggest the association of the Episomal pattern with samples of cervical desquamation cells with low-grade lesions, the association of the Mixed pattern of the HPV-16 genome with the genome of the CCUCa Ski cell line and the association of the Integrated pattern with the genome of the CCUSiHa cell line, as shown in Figure 3.
[0045] The IntG-HPV METHOD FOR DIRECT DETERMINATION OF PATTERNS OF THE PHYSICAL STATUS OF THE HPV GENOME IN RELATION TO THE GENOME OF INFECTED CELLS supports the industrial production of in vitro diagnostic kits for the diagnosis, prognosis, screening and prevention of Cervical Cancer, among other neoplasms, which are caused by high-oncological risk HPV subtypes.
[0046] zur Hausen (2002) relates HPV infection to the carcinogenesis of cervical cancer.
[0047] Dall et al. (2008) relates the inactivation of the E2 gene to the loss of gene control of the E6 and E7 genes.
[0048] Pett & Coleman (2007) observed that in cervical cancer, high-risk HPV subtypes 16 and 18 are integrated into the genome of cancer cells, with the HPV-16 subtype in 90% of cases and the HPV-18 subtype in 100% of the cases analyzed.
[0049] Yoshinouchi et al. (1999) suggest indirect analysis of HPV physical status relative analysis between the E2 and E6 gene.
[0050] Klaes et al. (1999) suggest indirect analysis of HPV physical status by analyzing HPV oncogenic transcripts.
[0051] Thorland et al. (2000) suggest indirect analysis of HPV physical status by amplifying the fusion region using specific primers and restriction enzymes.
[0052] Luft et al. (2001) suggest indirect analysis of HPV physical status by amplification of the integrated HPV sequence cross-pollinated with cellular sequences.
[0053] The reference to the deposit of biological material does not apply
[0054] The sequence listing is as follows:SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6 and SEQ ID NO:7.
[0055] The list of citations is as follows:
[0056] zur Hausen H. Nat Rev Cancer. 2002 May;2(5):342-50.
[0057] Zheng ZM, Baker CC. Front Biosci. 2006 Sep 1;11:2286-302.
[0058] Villa LL, Bernard HU, Kast M, et al. Virus Res. 2002 Nov;89(2):163-73.
[0059] Dall KL, Scarpini CG, Roberts I, et al. Cancer Res. 2008 Oct 15;68(20):8249-59.
[0060] Ghittoni R, Accardi R, Hassan U, et al. Virus Genes. 2010 Feb;40(1):1-13.
[0061] Castellsagué X, Ault KA, Bosch FX, et al. Papillomavirus Res. 2016 Dec;2:61-69.
[0062] de Sanjose S, Quint WG, Alemany L, et al. Lancet Oncol. 2010 Nov;11(11):1048-56.
[0063] Pett M, Coleman N. J Pathol. 2007 Aug;212(4):356-67.
[0064] Vinokurova S, Wentzensen N, Kraus I, et al. Cancer Res. 2008 Jan 1;68(1):307-13.
[0065] Klaes R, Woerner SM, Knight R, et al. Cancer Res. 1999 Dec 15;59(24):6132-6.
[0066] Yoshinouchi M, Fungus A, Nakamura K, et al. J Clin Microbiol. 1999 Nov;37(11):3514-7.
[0067] Luft F, Klaes R, Nees M, Dürst M, et al. Int J Cancer. 2001 Apr 1;92(1):9-17.
[0068] Thorland EC, Myers SL, Persing DH, et al. Cancer Res. 2000 Nov 1;60(21):5916-21.
[0069] PTL:1. US6355424
[0070] NPL:1. Publication entitled Analysis by multiplex PCR of the physical status of human papillomavirus type 16 DNA in cervical cancers. J Clin Microbiol. 1999 Nov;37(11):3514-7, by Yoshinouchi et al.
[0071] NPL:2. Publicação intitulada Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res. 1999 Dec 15;59(24):6132-6, por Klaes et al.
[0072] NPL:3. Publicação intitulada Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008 Jan 1;68(1):307-13, por Vinokurova et al.
Claims
THE IntG-HPV METHOD FOR DIRECT DETERMINATION OF PATTERNS OF THE PHYSICAL STATUS OF THE HPV GENOME IN RELATION TO THE GENOME OF INFECTED CELLS, characterized by using the action of the following components: a) set of primers specific for the IntG-HPV method, which present specific sequences for direct amplification of amplicons of the recombinant and non-recombinant regions of the HPV genome preferably by Multiplex-PCR; b) process of analysis of amplicons of the IntG-HPV method for direct determination of the physical status of HPV, which evaluate the presence or absence of amplicons for direct determination of the Episomal and Integrated molecular patterns of the HPV genome in relation to the genome of the infected cell;c) amplicon analysis process of the IntG-HPV method for indirect determination of the physical status of HPV, which evaluates the difference in intensity between the non-constant amplicons and the constant amplicon for determining the Mixed molecular pattern of the HPV genome in relation to the genome of the infected cell.; METHOD IintG-HPV, according to claim 1, characterized by being used in molecular diagnostic and prognostic testing for cancers caused by infection followed by integration of the viral genome into the genome of infected cells by directly determining the episomal and integrated molecular patterns of the HPV genome and other viruses, being preferably applied to the screening and prevention of Cervical Cancer - CC. IntG-HPV METHOD, according to claims 1 and 2, characterized by using natural samples of cell desquamation and / or biopsies from the genital tract and other tracts, being preferably applied to the screening and prevention of Cervical Cancer - CCU. KIT FOR DIRECT IN VITRO DETECTION OF EPISOMAL, MIXED AND INTEGRATED PATTERNS OF THE HPV GENOME TO THE GENOME OF THE INFECTED CELL IN NATURAL SAMPLES OF CELL DESCALATION AND / OR BIOPSIES OF THE GENITAL TRACT AND OTHER TRACTS, characterized by containing at least: mastermix for carrying out the Multiplex PCR reaction of the IntG-HPV method in a single step, according to claims 1, 2 and 3, characterized by preferably containing the reagents: the set of primers referring to the sequences SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6 and SEQ ID NO: 7 at least 50 ρMol each, dNTPs at least 10nM, Tris-HCl pH 8.8 at least 20 mM, DMSO at least 2%, hot start DNA polymerase at least 1IU and MgCl2 at least 2mM. KIT FOR DIRECT IN VITRO DETECTION OF EPISOMAL, MIXED AND INTEGRATED PATTERNS OF THE HPV GENOME IN THE GENOME OF INFECTED CELLS IN NATURAL SAMPLES OF CELL DESCUM AND / OR BIOPSIES OF THE GENITAL TRACT AND OTHER TREATS, according to claims 1, 2, 3 and 4, characterized by being used in in vitro diagnosis for direct determination of episomal, mixed and integrated molecular patterns of the HPV genome in natural samples of cell desquamation and / or biopsies of the genital tract and other tracts, being preferably applied to the screening and prevention of Cervical Cancer - CC.
Citation Information
Patent Citations
Association between integration of high-risk HPV genomes detected by molecular combing and the severity and / or clinical outcome of cervical lesions
US20200190607A1
Assessment of human papillomavirus-related disease
US6355424B1
